GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PT UBC Medical Indonesia Tbk LABS.JK · IDR

Health Care · IDX · 🇮🇩 Indonesia

Compare

121

-0.82%

Close of 9 Nov 2026, in IDR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Popular Bitcoin Ethereum Nvidia Apple S&P 500 Gold EUR/USD US 10Y

At a glance

Figures in IDR, from our data supplier.

FY2025

Revenue

IDR 199.30bn

FY2021FY2025

Net income

IDR 13.51bn

FY2021FY2025

Free cash flow

IDR 8.68bn

FY2021FY2025

Shareholders' equity

IDR 152.46bn

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueIDR 199.30bnIDR 147.64bnIDR 136.70bnIDR 93.29bnIDR 129.96bn
Gross profitIDR 67.46bnIDR 45.61bnIDR 46.51bnIDR 30.27bnIDR 53.10bn
Operating incomeIDR 20.37bnIDR 8.95bnIDR 5.84bnIDR 3.40bnIDR 3.19bn
Net incomeIDR 13.51bnIDR 2.95bnIDR 2.19bnIDR 2.83bnIDR 308.3m
Diluted earnings per share3.420.750.550.720.08

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsIDR 228.19bnIDR 203.60bnIDR 160.29bnIDR 108.73bnIDR 94.99bn
Cash and short-term investmentsIDR 41.16bnIDR 42.55bnIDR 3.62bnIDR 827.5mIDR 11.60bn
Total liabilitiesIDR 75.72bnIDR 64.84bnIDR 110.93bnIDR 61.26bnIDR 85.76bn
DebtIDR 27.50bnIDR 35.94bnIDR 41.42bnIDR 19.93bnIDR 31.22bn
Shareholders' equityIDR 152.46bnIDR 138.75bnIDR 49.36bnIDR 47.47bnIDR 9.23bn
Shares outstanding3,950m3,950m3,950m3,950m3,950m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsIDR 22.89bn−IDR 13.68bn−IDR 14.83bn−IDR 15.05bn−IDR 20.63bn
Capital spending−IDR 14.21bn−IDR 6.81bn−IDR 20.12bn−IDR 3.89bn−IDR 11.71bn
Free cash flowIDR 8.68bn−IDR 20.49bn−IDR 34.95bn−IDR 18.94bn−IDR 32.34bn

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueIDR 55.20bnIDR 40.02bnIDR 63.86bnIDR 48.74bnIDR 53.23bnIDR 33.46bnIDR 41.21bnIDR 41.89bn
Gross profitIDR 17.78bnIDR 15.54bnIDR 22.82bnIDR 17.98bnIDR 14.73bnIDR 11.93bnIDR 9.58bnIDR 14.58bn
Operating incomeIDR 6.39bnIDR 843.7mIDR 7.48bnIDR 5.97bnIDR 3.83bnIDR 3.09bnIDR 2.04bnIDR 3.64bn
Net incomeIDR 3.83bnIDR 409.6mIDR 1.54bnIDR 4.91bnIDR 5.21bnIDR 1.85bn−IDR 2.66bnIDR 3.85bn
Diluted earnings per share0.970.100.391.241.320.47-0.670.97
Cash from operations−IDR 6.81bn−IDR 19.49bnIDR 30.34bnIDR 9.43bn−IDR 3.62bn—IDR 26.51bn−IDR 30.91bn
Capital spending−IDR 1.58bn−IDR 2.58bn−IDR 12.59bn−IDR 1.28bn−IDR 231.0m—−IDR 931.0m−IDR 2.70bn
Free cash flow−IDR 8.39bn−IDR 22.07bnIDR 17.75bnIDR 8.15bn−IDR 3.85bn—IDR 25.58bn−IDR 33.61bn
Total assetsIDR 223.35bnIDR 218.61bnIDR 228.19bnIDR 217.49bnIDR 209.16bnIDR 211.96bnIDR 203.60bnIDR 237.47bn
Cash and short-term investmentsIDR 6.86bnIDR 18.42bnIDR 41.16bnIDR 25.11bnIDR 17.24bnIDR 29.07bnIDR 42.55bnIDR 43.34bn
DebtIDR 23.05bnIDR 25.51bnIDR 25.84bnIDR 26.13bnIDR 25.45bnIDR 26.95bnIDR 27.06bnIDR 25.46bn
Shareholders' equityIDR 156.70bnIDR 152.87bnIDR 152.46bnIDR 150.72bnIDR 145.81bnIDR 140.60bnIDR 138.75bnIDR 141.62bn

Financial ratios

Data as of 31 Aug 2026

FY2025FY2024FY2023FY2022FY2021
Gross margin33.8%30.9%34.0%32.4%40.9%
Operating margin9.4%5.6%6.1%6.5%2.2%
Net margin6.8%2.0%1.6%3.0%0.2%
Return on equity8.9%2.1%4.4%6.0%3.3%
Return on assets5.9%1.5%1.4%2.6%0.3%
Free cash flow yield5.8%-1.1%———
Revenue growth35.0%8.0%46.5%-28.2%—
Earnings growth357.5%34.8%-22.7%819.4%—
Current ratio2.52x3.02x1.23x0.99x0.70x
Debt to equity0.17x0.19x0.45x0.42x3.23x
Equity ratio66.8%68.2%30.8%43.7%9.7%
Interest coverage15.06x2.74x3.89x3.91x24.88x
Buybacks as a share of market value0.0%————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue28.8%——
Operating income81.7%——
Net income68.3%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin32.6%32.9%——

Valuation history

At each fiscal year end

FY2025FY2024
Price to earnings40.1179.3
Price to sales2.73.6

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.